TwinBeech Capital’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
TwinBeech Capital's ACAD Position: Q3 2026 in Review
TwinBeech Capital opened a new position in Acadia Pharmaceuticals (ACAD) in Q3 2026: 32,145 shares worth $648K. The stake represents 0.15% of the portfolio and ranks #192 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in ACAD as recently as Q3 2024.
TwinBeech Capital first reported a position in ACAD in Q3 2020 and has held it in 11 quarters since. The position peaked at $6.6M in Q3 2023. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- TwinBeech Capital held 32,145 shares of Acadia Pharmaceuticals worth $648K as of Q3 2026.
- Acadia Pharmaceuticals was a new TwinBeech Capital position in Q3 2026.
- Acadia Pharmaceuticals made up 0.15% of TwinBeech Capital's portfolio in Q3 2026, its #192 holding.
- TwinBeech Capital first reported a position in Acadia Pharmaceuticals in Q3 2020 and has held it in 11 quarters since.
- TwinBeech Capital's Acadia Pharmaceuticals position peaked at $6.6M in Q3 2023.
- 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on TwinBeech Capital's 13F filing for Q3 2026, filed 16 Nov 2026.